AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32933498 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative induction chemotherapy (2 cycles of FLOT: 5‐FU, leucovorin, oxaliplatin, docetaxel) followed by preoperative radiochemotherapy (oxaliplatin weekly, 5‐FU plus concurrent fractioned radiotherapy to a dose of 45 Gy)
Number of subjects: 340
Study 32933498 — intervention group
Group type: COMPARATOR
Intervention: Preoperative chemotherapy alone (4 cycles of FLOT)
Number of subjects: 340
Study 32933498 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined chemotherapy/radiochemotherapy treatment
Number of subjects: 340
Study 32933498 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative induction chemotherapy (2 cycles of FLOT) followed by preoperative radiochemotherapy
Number of subjects: 340
Study 32933498 — intervention group
Group type: COMPARATOR
Intervention: Preoperative chemotherapy with FLOT alone
Number of subjects: 340
Study 36475294 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide 3 mg/day
Number of subjects: 135
Study 36475294 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 135
Study 32506882 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic mixture containing Bifidobacterium animalis subsp. lactis BB-12 and Enterococcus faecium L3
Number of subjects: 94
Study 32506882 — intervention group
Group type: COMPARATOR
Intervention: Control group of 109 healthy, untreated subjects
Number of subjects: 94
Study 34184369 — intervention group
Group type: EXPERIMENTAL
Intervention: Video consultation invitation (default option)
Number of subjects: 1481
Study 34184369 — intervention group
Group type: EXPERIMENTAL
Intervention: Active choice invitation (choose between in-person or video)
Number of subjects: 1481
Study 34184369 — intervention group
Group type: COMPARATOR
Intervention: In-person invitation (default option)
Number of subjects: 1481
Study 33528516 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-mg/d Vericiguat
Number of subjects: 0
Study 33528516 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-mg/d Vericiguat
Number of subjects: 0
Study 33528516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35620203 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascia iliac compartment block (FICB)
Number of subjects: 231
Study 35620203 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (control group)
Number of subjects: 231
Study 34341196 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual separation followed by topical antibiotic ointment application for 1 week with local hygiene
Number of subjects: 48
Study 35917993 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS) administered prior to initial acquisition of a predictive learning task
Number of subjects: 0
Study 35917993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35917993 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS)
Number of subjects: 0
Study 32844292 — intervention group
Group type: EXPERIMENTAL
Intervention: Native cholecalciferol
Number of subjects: 30
Study 32844292 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol
Number of subjects: 30
Study 34994708 — intervention group
Group type: EXPERIMENTAL
Intervention: App-based relaxation exercises (including audio-based autogenic training, mindfulness meditation, or guided imagery)
Number of subjects: 220
Study 34994708 — intervention group
Group type: COMPARATOR
Intervention: Usual care and app for data entry only (Control)
Number of subjects: 220
Study 34994708 — intervention group
Group type: EXPERIMENTAL
Intervention: App-based relaxation exercises
Number of subjects: 220
Study 34147923 — intervention group
Group type: EXPERIMENTAL
Intervention: taVNS at 2 mA
Number of subjects: 0
Study 34147923 — intervention group
Group type: COMPARATOR
Intervention: Control stimulation at 2 mA
Number of subjects: 0
Study 32553252 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement
Number of subjects: 435
Study 32553252 — intervention group
Group type: COMPARATOR
Intervention: Surgical valve replacement
Number of subjects: 435
Study 32553252 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 435
Study 35351196 — intervention group
Group type: COMPARATOR
Intervention: CAF + PL
Number of subjects: 16
Study 35351196 — intervention group
Group type: EXPERIMENTAL
Intervention: BJ + CAF
Number of subjects: 16
Study 34043103 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin as first- or second-line chemotherapy
Number of subjects: 0
Study 34043103 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 33485468 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 µg with Algel-IMDG
Number of subjects: 375
Study 33485468 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 µg with Algel-IMDG
Number of subjects: 375
Study 33485468 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 µg with Algel
Number of subjects: 375
Study 33485468 — intervention group
Group type: COMPARATOR
Intervention: Algel only (control)
Number of subjects: 375
Study 32441331 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate‐ to high‐intensity aerobic and strength exercise program
Number of subjects: 494
Study 32441331 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 494
Study 34324377 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital intervention (text messaging)
Number of subjects: 21
Study 34324377 — intervention group
Group type: COMPARATOR
Intervention: Control group (medical facts)
Number of subjects: 21
Study 33054742 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised scripted lesson plans for HIV and sexual content in life orientation curriculum (implemented in 55 schools).
Number of subjects: 2802
Study 33054742 — intervention group
Group type: COMPARATOR
Intervention: Control group (50 schools).
Number of subjects: 2802
Study 34110839 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU + ApBM (12-session approach bias modification training)
Number of subjects: 729
Study 34110839 — intervention group
Group type: COMPARATOR
Intervention: TAU-only (treatment as usual)
Number of subjects: 729
Study 34110839 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU + ApBM
Number of subjects: 729
Study 34110839 — intervention group
Group type: COMPARATOR
Intervention: TAU-only
Number of subjects: 729
Study 33667194 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose testosterone (T)
Number of subjects: 26
Study 33667194 — intervention group
Group type: COMPARATOR
Intervention: Aromatase inhibitor letrozole (Lz)
Number of subjects: 26
Study 33667194 — intervention group
Group type: EXPERIMENTAL
Intervention: All boys (combined results)
Number of subjects: 26
Study 35297176 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirming implementation intentions (S-AII)
Number of subjects: 130
Study 35297176 — intervention group
Group type: COMPARATOR
Intervention: Non-affirming implementation intentions (active control)
Number of subjects: 130
Study 35297176 — intervention group
Group type: COMPARATOR
Intervention: Mere goal intentions (non-active control)
Number of subjects: 130
Study 32859334 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean dietary pattern (MDP)
Number of subjects: 357
Study 32859334 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 357
Study 35277406 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 0
Study 35277406 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 0
Study 33619855 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infusion of ropivacaine
Number of subjects: 18
Study 33619855 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 18
Study 616701079 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention (listening to music for 30 minutes)
Number of subjects: 85
Study 616701079 — intervention group
Group type: COMPARATOR
Intervention: Control (wearing headphones with no music for 30 minutes)
Number of subjects: 85
Study 35897025 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 120
Study 35897025 — intervention group
Group type: COMPARATOR
Intervention: Artificial Tears (AT)
Number of subjects: 120
Study 33789432 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry Needling Combined With Guideline‐Based Physical Therapy
Number of subjects: 0
Study 33789432 — intervention group
Group type: COMPARATOR
Intervention: Guideline‐Based Physical Therapy
Number of subjects: 0
Study 32549148 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to Second Hand Smoking (SHS)
Number of subjects: 789
Study 32549148 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge about SHS
Number of subjects: 789
Study 32549148 — intervention group
Group type: EXPERIMENTAL
Intervention: Response to SHS exposure
Number of subjects: 789
Study 36480102 — intervention group
Group type: EXPERIMENTAL
Intervention: One Anastomosis Gastric Bypass (OAGB)
Number of subjects: 335
Study 36480102 — intervention group
Group type: COMPARATOR
Intervention: Sleeve Gastrectomy (SG)
Number of subjects: 335
Study 36480102 — intervention group
Group type: EXPERIMENTAL
Intervention: Both OAGB and SG
Number of subjects: 335
Study 36480102 — intervention group
Group type: EXPERIMENTAL
Intervention: OAGB
Number of subjects: 335
Study 36480102 — intervention group
Group type: COMPARATOR
Intervention: SG
Number of subjects: 335
Study 34600589 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 receptor antagonists (IL-6RAs)
Number of subjects: 860
Study 34600589 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (IL-6RAs and steroids)
Number of subjects: 860
Study 34600589 — intervention group
Group type: COMPARATOR
Intervention: Steroids
Number of subjects: 860
Study 32339359 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD Coach (n=33)
Number of subjects: 64
Study 32339359 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU; n=31)
Number of subjects: 64
Study 33724264 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D (Cardiac Resynchronization and Defibrillator Therapy)
Number of subjects: 0
Study 33724264 — intervention group
Group type: COMPARATOR
Intervention: CRT-P (CRT Alone)
Number of subjects: 0
Study 33068691 — intervention group
Group type: COMPARATOR
Intervention: EX + placebo (EX0)
Number of subjects: 60
Study 33068691 — intervention group
Group type: EXPERIMENTAL
Intervention: EX + 500 mg/day resveratrol (EX500)
Number of subjects: 60
Study 33068691 — intervention group
Group type: EXPERIMENTAL
Intervention: EX + 1000 mg/day resveratrol (EX1000)
Number of subjects: 60
Study 32247660 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibuprofen (10 mg/kg) plus acetaminophen (15 mg/kg)
Number of subjects: 90
Study 32247660 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen (15 mg/kg)
Number of subjects: 90
Study 32247660 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (10 mg/kg)
Number of subjects: 90
Study 33197226 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg every 2 weeks
Number of subjects: 499
Study 33197226 — intervention group
Group type: COMPARATOR
Intervention: Continued chemotherapy
Number of subjects: 499
Study 33197226 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab in PD-L1-positive population (n = 54)
Number of subjects: 499
Study 33197226 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab in exploratory analysis of PD-L1-positive population (n = 137)
Number of subjects: 499
Study 33197226 — intervention group
Group type: COMPARATOR
Intervention: Continued chemotherapy in exploratory analysis of PD-L1-positive population (n = 137)
Number of subjects: 499
Study 33197226 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab
Number of subjects: 499
Study 32345730 — intervention group
Group type: EXPERIMENTAL
Intervention: NF1 germline mutations
Number of subjects: 29
Study 34510020 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine-based resistance training protocol (3 times a week for 6 weeks)
Number of subjects: 11
Study 34510020 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 11
Study 32172171 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA stimulation
Number of subjects: 13
Study 32172171 — intervention group
Group type: COMPARATOR
Intervention: VIM stimulation
Number of subjects: 13
Study 35072758 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol (100 mg daily) + Sertraline (100 mg daily)
Number of subjects: 54
Study 35072758 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Sertraline (100 mg daily)
Number of subjects: 54
Study 34708642 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingre Huatan formulae + Western Medicine
Number of subjects: 60
Study 34708642 — intervention group
Group type: COMPARATOR
Intervention: Conventional Western Medicine only
Number of subjects: 60
Study 34988730 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal tranexamic acid injection combined with low fluence Q-switched Nd:YAG laser
Number of subjects: 40
Study 34988730 — intervention group
Group type: COMPARATOR
Intervention: Intradermal tranexamic acid injection alone
Number of subjects: 40
Study 33308035 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise for 20 minutes
Number of subjects: 150
Study 33308035 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported engagement in moderate-to-vigorous physical activity
Number of subjects: 150
Study 33308035 — intervention group
Group type: COMPARATOR
Intervention: Control group (viewed a time matched video)
Number of subjects: 150
Study 32588049 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher waist-hip ratio (WHR)
Number of subjects: 451097
Study 32588049 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher WHR adjusted for BMI
Number of subjects: 451097
Study 32588049 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher body mass index (BMI)
Number of subjects: 451097
Study 32588049 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher body-fat percentage
Number of subjects: 451097
Study 32588049 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee consumption
Number of subjects: 451097
Study 32588049 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking status and frequency
Number of subjects: 451097
Study 35938276 — intervention group
Group type: EXPERIMENTAL
Intervention: APMaT (workplace alcohol prevention program)
Number of subjects: 187
Study 35938276 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 187
Study 33197270 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% ibuprofen gel
Number of subjects: 22
Study 33197270 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025% capsaicin cream
Number of subjects: 22
Study 33197270 — intervention group
Group type: COMPARATOR
Intervention: Comparison of ibuprofen and capsaicin
Number of subjects: 22
Study 34013569 — intervention group
Group type: EXPERIMENTAL
Intervention: Registered RCTs (66/155, 42.6%)
Number of subjects: 155
Study 34013569 — intervention group
Group type: EXPERIMENTAL
Intervention: Each additional year of publication
Number of subjects: 155
Study 32635181 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B‐6 (50 mg pyridoxine/d)
Number of subjects: 61
Study 32635181 — intervention group
Group type: EXPERIMENTAL
Intervention: GSH (500 mg/d)
Number of subjects: 61
Study 32635181 — intervention group
Group type: EXPERIMENTAL
Intervention: B‐6 + GSH
Number of subjects: 61
Study 32635181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 32635181 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of GSH, high GSH/oxidized GSH ratio, and high GSH-St activity at baseline
Number of subjects: 61
Study 35971130 — intervention group
Group type: EXPERIMENTAL
Intervention: Everyday Life Rehabilitation (ELR) plus treatment as usual (TAU)
Number of subjects: 0
Study 35971130 — intervention group
Group type: EXPERIMENTAL
Intervention: Everyday Life Rehabilitation (ELR)
Number of subjects: 0
Study 35971130 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study 33551217 — intervention group
Group type: EXPERIMENTAL
Intervention: High fructose diet (HiFruD, 1.4 g kg−1 day−1 fructose + 0.1 g kg−1 day−1 glucose)
Number of subjects: 12
Study 33551217 — intervention group
Group type: EXPERIMENTAL
Intervention: High fructose diet (HiFruD)
Number of subjects: 12
Study 33551217 — intervention group
Group type: COMPARATOR
Intervention: Low fructose diet (LoFruD, <10 g/d)
Number of subjects: 12
Study 32767824 — intervention group
Group type: EXPERIMENTAL
Intervention: t‐VNS
Number of subjects: 33
Study 32767824 — intervention group
Group type: COMPARATOR
Intervention: sham
Number of subjects: 33
Study 35574968 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity interval training (HIIT) for 6 months
Number of subjects: 60
Study 35574968 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group) for 6 months
Number of subjects: 60
Study 33639906 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended learning
Number of subjects: 37
Study 33639906 — intervention group
Group type: COMPARATOR
Intervention: E-learning
Number of subjects: 37
Study 33639906 — intervention group
Group type: COMPARATOR
Intervention: Lecture group
Number of subjects: 37
Study 33639906 — intervention group
Group type: COMPARATOR
Intervention: All groups (Blended, E-learning, Lecture)
Number of subjects: 37
Study 34171880 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.5% without epinephrine)
Number of subjects: 130
Study 34171880 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 130
Study 32803824 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol beverage
Number of subjects: 158
Study 32803824 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 158
Study 32803824 — intervention group
Group type: COMPARATOR
Intervention: Control beverage
Number of subjects: 158
Study 34268773 — intervention group
Group type: EXPERIMENTAL
Intervention: suppression
Number of subjects: 80
Study 34268773 — intervention group
Group type: EXPERIMENTAL
Intervention: acceptance
Number of subjects: 80
Study 34268773 — intervention group
Group type: COMPARATOR
Intervention: control
Number of subjects: 80
Study 33685411 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevenar13™ (P) at 2–4‐6 months (_PPP)
Number of subjects: 425
Study 33685411 — intervention group
Group type: EXPERIMENTAL
Intervention: Synflorix™ (S) at 2–4‐6 months (_SSS)
Number of subjects: 425
Study 33685411 — intervention group
Group type: EXPERIMENTAL
Intervention: Synflorix™ at 1–2‐4 months plus Prevenar13™ at 6 months (SSSP)
Number of subjects: 425
Study 33685411 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group (all interventions)
Number of subjects: 425
Study 33685411 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 425
Study 32950036 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential phototherapy unit
Number of subjects: 42
Study 32950036 — intervention group
Group type: COMPARATOR
Intervention: Ordinary phototherapy unit
Number of subjects: 42
Study 34564755 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Intermittent Exercise (HIIE) during Follicular Phase (FP)
Number of subjects: 14
Study 34564755 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Intermittent Exercise (HIIE) during Luteal Phase (LP)
Number of subjects: 14
Study 34564755 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Intermittent Exercise (HIIE) during both phases
Number of subjects: 14
Study 32555695 — intervention group
Group type: COMPARATOR
Intervention: Tadalafil (placebo arm of a phase 3 trial)
Number of subjects: 371
Study 32555695 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic score adjustment in randomized trials
Number of subjects: 371
Study 32555695 — intervention group
Group type: EXPERIMENTAL
Intervention: Combining measures of ambulatory function
Number of subjects: 371
Study 32555695 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized clinical trials with validated prognostic score
Number of subjects: 371
Study 33185824 — intervention group
Group type: EXPERIMENTAL
Intervention: Harm Reduction Treatment for Alcohol (HaRT‐A)
Number of subjects: 168
Study 33185824 — intervention group
Group type: COMPARATOR
Intervention: Services as usual
Number of subjects: 168
Study 36343988 — intervention group
Group type: EXPERIMENTAL
Intervention: Insoles adapted in flip-flop sandals
Number of subjects: 80
Study 36343988 — intervention group
Group type: COMPARATOR
Intervention: Flip-flop sandals with sham (flat) insoles
Number of subjects: 80
Study 34461931 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-offset CSA plus tailored nutrition education
Number of subjects: 305
Study 34461931 — intervention group
Group type: COMPARATOR
Intervention: Control (delayed intervention)
Number of subjects: 305
Study 33576828 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonverbal communication strategies and social cues used by pediatricians during mask-wearing encounters.
Number of subjects: 0
Study 32184026 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose of ready-to-use therapeutic food (RUTF)
Number of subjects: 452
Study 32184026 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced dose of ready-to-use therapeutic food (RUTF)
Number of subjects: 452
Study 32184026 — intervention group
Group type: COMPARATOR
Intervention: Community controls
Number of subjects: 452
Study 35896378 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 200 mg once daily for 2 weeks
Number of subjects: 121
Study 35896378 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 200 mg once daily for 6 weeks
Number of subjects: 121
Study 35896378 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks after 2 weeks of doxycycline
Number of subjects: 121
Study 33427382 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication skill training (CST) for APNs, 6 hours under guidance of facilitators and simulated patients
Number of subjects: 61
Study 33427382 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CST)
Number of subjects: 61
Study 33427382 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication skill training (CST) for APNs
Number of subjects: 61
Study 32727748 — intervention group
Group type: EXPERIMENTAL
Intervention: High inferior mesenteric artery ligation (Group 1)
Number of subjects: 46
Study 32727748 — intervention group
Group type: COMPARATOR
Intervention: Low inferior mesenteric artery ligation (Group 2)
Number of subjects: 46